retatrutide ly3437943 triple agonist gip glp-1 glucagon Structural insights into the agonism at GLP-1R, GIPR and GCGR manifested by Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Phase 2 trials used a starting dose of 2 mg once weekly subcutaneously, escalating at approximately 4-weekly intervals to maintenance doses of 4 mg, 8 mg, or 12 mg

It is necessary to monitor the long-term safety of GLP-1 mimetic therapies, as well as to examine GLP-1R as a possible molecular target for the diagnosis and treatment of advanced PDACs

doi: 10.1007/s12035-024-04470-4, 230 YangG.LobarinasE.ZhangL.TurnerJ.StolzbergD.SalviR.et al

Julianna Lindsey (16:32.595) I can tell you with certainty that most people who are eating a high fat diet are going to have higher cholesterol levels

Sip water consistently throughout the day